Cervix
DCEG researchers conduct studies on cancers of the cervix, more commonly referred to as cervical cancer. The primary cause of cervical cancer is persistent infection with the human papillomavirus (HPV). Selected studies include:
-
ASC-US,LSIL Triage Study (ALTS)
A study of the clinical management of low-grade cervical cytologic abnormalities
-
Biopsy Study to Improve Detection of Cervical Precancer
A collaborative study on colposcopic biopsy with aims to study cervical disease on the lesion level, optimize criteria for biopsy placement, and analyze the incremental benefit of taking multiple biopsies
-
Cervical Cancer Screening Among HIV-Infected Women in India
A study to evaluate a cohort of HIV-infected women using two novel and potentially sustainable, lower-cost tests for accurate screening for cervical cancer
-
Guanacaste HPV Natural History Study
A population-based natural history study of HPV and cervical neoplasia launched with Costa Rican colleagues in 1993.
-
Human Papillomavirus (HPV) Cervical Cancer Risk Prediction
Human Papillomavirus (HPV) Cervical Cancer Risk Prediction
-
Human Papillomavirus (HPV) Cervical Visualization Study
Human Papillomavirus (HPV) Cervical Visualization Study
-
HPV Vaccine Trial in Costa Rica (CVT)
A randomized, controlled phase III trial of a vaccine to prevent human papillomavirus (HPV) 16 and 18 infections and their associated cervical lesions in Costa Rica (CVT)
-
Human Papillomavirus (HPV) Genomics Project
A project to interrogate the relationship between sequence changes in the HPV viral genome and carcinogenicity.
-
Human Papillomavirus (HPV) Methylation
Study of methylation of the HPV viral genome and risk of cervical intraepithelial neoplasia 3+ to prevent cervical cancer
-
Human Papillomavirus (HPV) Natural History, Genomics and Risk Assessment
Studies of human papillomavirus (HPV) natural history, genomics and risk assessment that led to advances in screening and clinical management
-
Human Papillomavirus (HPV) Persistence and Progression Cohort (PaP Cohort)
The Persistence and Progression Cohort (PaP Cohort) is a collaborative study with Kaiser Permanente Northern California to create a repository of specimens for natural history studies, HPV typing, methylation, and HPV variant genomics.
-
Improvement of Risk-Informed Screening (IRIS)
A comprehensive evaluation of candidate biomarkers for use in cervical cancer screening and triage.
-
PRIMAVERA*-ESCUDDO Trial to Compare One Dose of Bivalent HPV Vaccine to Three Doses of Quadrivalent Vaccine
Non-inferiority trial comparing immunogenicity from one dose of bivalent HPV vaccine in girls to three doses of quadrivalent vaccine in women: The PRIMAVERA*-ESCUDDO Trial
-
Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines—The ESCUDDO* Study
Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines--the ESCUDDO study (Estudio de Comparacion de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano (VPH)).
-
STRIDES: Studying Risk and Improving Disparities of Cervical Cancer in Mississippi
The NCI is partnering with the University of Mississippi Medical Center to evaluate risk of cervical precancer and to study novel biomarkers in women undergoing cervical cancer screening.
-
Study to Understand Cervical Cancer Early Endpoints and Determinants (SUCCEED)
A study to comprehensively assess biomarkers of risk for progressive cervical neoplasia, and thus develop a new set of biomarkers that can distinguish those at highest risk of cervical cancer from those with benign infection
Research in Action
Mark Schiffman uses molecular epidemiology to predict and prevent cervical cancer.
Article & Video: Taking the Long View